DES(1-3) IGF-1: Research, Dosing, and Where to Buy in 2026
A research-first profile for DES(1-3) IGF-1 (DES, DES IGF-1), aggregating mechanism notes, transcript dosing mentions, vendor recommendations, and PubMed-indexed literature without presenting medical guidance.
DES(1-3) IGF-1 is a research compound profiled here from named-expert transcripts and peer-reviewed literature, without medical guidance. As of July 2026, The Peptide Wiki aggregates 8 PubMed-cited papers, and 1 transcript dosing protocol for DES(1-3) IGF-1, each linked to its source.
- Also indexed as DES, DES IGF-1.
- 1 aggregated dosing-protocol mention from source transcripts.
- 8 PubMed-indexed citations listed in the research table below.
- 0 vendor recommendations captured from named experts.
What is DES(1-3) IGF-1?
Research compound aggregated from creator and literature mentions. No direct disease-treatment claims are made on this page.
DES(1-3) IGF-1 Dosing Protocols
The entries below are transcript-derived dosing mentions. They are preserved for research context and are not medical advice.
| Speaker | Source | Timestamp | Protocol | Evidence |
|---|---|---|---|---|
| Trensparent with Nyle Nayga | Broderick Chavez: The Best Way To Grow Fast (PED’s, GH, Insulin, IGF-1, etc) | 01:21:52 | Users have reported administering IGF-1 DES locally into the target muscle at maximum pump; one reported example protocol used 125 micrograms injected into the bicep at peak pump. | anecdotal |
Where to Buy DES(1-3) IGF-1 in 2026
No tracked vendor recommendations for DES(1-3) IGF-1 yet. See our vendor directory.
Side Effects and Safety
Anecdotal reports and study-level observations vary by route, dose, and individual. This page does not provide medical advice. Consult a qualified clinician before any research use.
User Reviews
User reviews aggregator coming Q3 2026 (Reddit + YouTube comments + Discord research notes). Until then, see the expert quote section above and PubMed citations below.
Research Efficacy Snapshot
Published efficacy percentages cited in PubMed trials and named-expert reports about DES(1-3) IGF-1. Each line links to the original source.
- "By 23 months of age, 53% of the WAP-DES mice developed mammary adenocarcinomas." · Hadsell D et al, 2000 PubMed
- "A 75% reduction in both apoptosis and proliferation was observed in the normal mammary glands of WAP-DES mice." · Hadsell D et al, 2000 PubMed
- "Effects of insulin-like growth factor I (IGF-I) administration and that of the truncated analogue des-(1-3)IGF-I have been examined in 170-g rats over a 7-day period after surgery to remove 80% of the jejunum plus ileum." · Lemmey A et al, 1991 PubMed
Research and Studies
8 PubMed-indexed papers reference DES(1-3) IGF-1. Top 8 shown.
Legal Status
DES(1-3) IGF-1 is presented here as a research compound. FDA approval status, scheduling, WADA status, and state-specific telehealth rules may apply. Always verify current regulatory status. Last verified: 2026-07-09.
Frequently Asked Questions
Is DES(1-3) IGF-1 FDA-approved?
DES(1-3) IGF-1 is presented on this page as a research compound. FDA approval status, scheduling, and state-specific rules may apply and change. Verify current regulatory status before any decision.
What dosing is reported for DES(1-3) IGF-1?
This page aggregates 1 dosing-protocol mention(s) from named-expert transcripts, each linked to a verbatim source timestamp. See the Dosing Protocols table above. Mentions are anecdotal, not medical advice.
How much research has been published on DES(1-3) IGF-1?
8 PubMed-indexed paper(s) reference DES(1-3) IGF-1 in our current research feed. See the Research and Studies section above for citations.